Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
Recruiting now Phase 4 NCT07094048
Run by CHU de Quebec-Universite Laval · for 18 and older · All sexes
What this study is about
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
Who can join (things the study team will check)
✅ You may be able to join if…
- Multiple myeloma patient:
- ≥ 18 years old
- ≥ 1 prior lines of therapy
- Receiving a BCMA-directed T-cell Engager therapy (starting on treatment)
- On previous Ig support or not
🚫 You may not be able to join if…
- Less than 18 years old
- Pregancy or breastfeeding
Where this trial is running
- Centre Intégré de Cancérologie, Québec, Quebec, Canada
Who to contact
Philippe Nadeau, PhD · 1-418-525-4444 · philippe.nadeau@chudequebec.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07094048.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.